The regulatory file for pancreatin, a three-activity gland extract
Pancreatin is a glandular extract with three enzyme activities, and its regulatory file is built around the species, the activities, the carrier and the intended use. In the EU a food enzyme sits under Regulation (EC) No 1332/2008; in the US the supplement route and the prescription pancrelipase route are separate; in the UK the GB and Northern Ireland positions are checked separately. The buyer's regulatory team confirms the route for the destination, and this page lists the evidence and checks that belong in the file.
The file has to show the species, the three activities, the carrier and the intended use, because a food enzyme, a supplement ingredient and a pharmacopoeial article are three different routes.
Four checks, not one
The file answers four questions: whether the material may be used in the intended food or supplement in that market; whether the lot meets the contaminant and microbiological limits; how it is described on the label, including the carrier; and what the brand says about it. Permission, purity, labelling and claims are four different checks, and a certificate of analysis answers only the second one.
Pancreatin is a tissue extract, so the source belongs in the file: hog or ox pancreas, the tissue record and the species statement. The grade matters too. A product sold against a pharmacopoeial monograph is a different article from a food-grade powder with the same three activity figures, and the file should say which one is being bought. The specification, the certificate and the label should all refer to the same revision.
European Union
Food enzymes fall under Regulation (EC) No 1332/2008. The regulation requires an enzyme to be included in the Union list before it is placed on the market or used in food, but the Union list has not been adopted. Article 24 provides that, until the list applies, national provisions on the placing on the market and use of food enzymes continue to apply in the member states. As of this review the list is still pending; check the current text before a launch.
The file should show the application or register entry that covers the enzyme and its intended use, and the member state of sale should be named, not only “the EU”. Labelling and the carrier statement are checked separately: a lactose dilution brings a milk-derived allergen into the declaration. Great Britain applies assimilated Regulation 1332/2008 and keeps its own register; Northern Ireland follows the EU framework, and the two are checked separately.
United States
In the United States, pancrelipase is the active substance of FDA-approved prescription products. A pancreatin ingredient for a supplement or a food use sits on a different route: the brand's regulatory team confirms whether it qualifies as an old dietary ingredient, whether a GRAS basis covers the food use, and how the Supplement Facts panel names it. The certificate does not answer that question.
Labelling follows the route. For a food use, an enzyme that has no technical effect in the finished food may be exempt from ingredient declaration as a processing aid; an enzyme that remains active and functional is not. For a supplement, the panel declares the ingredient and the amount, and the three activities belong in the specification rather than in the panel. The claim is reviewed separately from both.
Contaminants and limits
| Parameter | Catalog limit | Market note |
|---|---|---|
| Lead | ≤3 mg/kg | EU food supplements: 3.0 mg/kg as sold |
| Cadmium | ≤1 mg/kg | EU food supplements: 1.0 mg/kg as sold |
| Mercury | ≤0.1 mg/kg | EU food supplements: 0.10 mg/kg as sold |
| Arsenic | ≤2 mg/kg | No general EU maximum for this matrix; the specification sets the limit |
| Microbiology | APC ≤1,000 cfu/g; yeast and mould ≤100 cfu/g; E. coli and Salmonella absent | General food-safety duty; the customer specification may be tighter |
| Loss on drying | ≤5.0% | Quality parameter; it also sets the activity basis |
The EU ceilings apply to the supplement as sold, not to the powder. The ingredient limit has to be set so that the finished product stays under the ceiling; the brand does that calculation, and the COA is an input. For a pharmacopoeial article the monograph adds its own fat and microbial requirements.
What the label and the claim may say
No disease-related claim is made for this material, and the technical pages describe the specification and the file, not a physiological effect. “Amylase ≥25, protease ≥25, lipase ≥2 USP U/mg” is a statement about the preparation, not a health claim.
A statement about what the finished product does in the body is a claim, and it belongs to the brand and to the market where it is made. The EU health-claims regulation, the US supplement rules and the retained UK regime each set their own test. The enzyme file supports identity, activity and purity; it does not support a claim.
The document pack
- Specification with the unit definitions and the assay conditions.
- Batch COA with the three results, the ratio and the release limits.
- Technical data sheet with activity, solubility, particle size and packing.
- Safety data sheet with the dust and exposure controls.
- Allergen statement covering the species and the carrier.
- Species and tissue record, with the origin of the pancreas.
- Carrier and composition statement.
- Stability summary for the grade and the pack.
- Pharmacopoeial statement if the lot is bought against the monograph.
Compliance checklist
| Check | Evidence |
|---|---|
| Market and intended use named | Regulatory basis memo for that use |
| Species and tissue record | Origin statement and production record |
| Grade and monograph position | Specification revision and the pharmacopoeial statement where relevant |
| Contaminants within the destination limit | Batch COA and, where needed, a third-party report |
| Carrier and allergen checked | Composition statement and label artwork |
| Label wording checked | Three activities, units, carrier and storage statement |
| Claims reviewed | Claim file owned by the brand |
| Documents complete | The list above, in the version released with the lot |
The catalog position is on the pancreatin product page; the release lines are on the COA page; the source and activity evidence is on the identity page; the market frameworks are summarised in the EU and US regulatory notes; the release workflow is on the quality page.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation